CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3 MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Increasing preference for non-invasive techniques over invasive methods
4.1.2. Improving reimbursement scenario for NIPT
4.1.3. The launch of new and advanced products
4.1.4. Programs focusing on increasing the awareness of NIPT
4.2. Market Restraints & Challenges
4.2.1. Lack of skilled professionals
4.2.2. Reliability of test results especially in obese women
4.3. Market Opportunities
4.3.1. Emerging markets
CHAPTER 5. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET – BY
METHOD
5.1. Introduction
5.2. Cell-Free DNA in Maternal Plasma Tests
5.3. Biochemical Screening Tests
5.4. Ultrasound Detection
5.5. Fetal Cells in Maternal Blood Tests
CHAPTER 6. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET – BY
PRODUCT
6.1. Introduction
6.2. Instruments
6.2.1. Ultrasound Devices
6.2.2. Next-Generation Sequencing Systems
6.2.3. Polymerase Chain Reaction Instruments
6.2.4. Microarrays
6.2.5. Other Instruments
6.3. Consumables
6.3.1. Assay Kits & Reagents
6.3.2. Disposables
CHAPTER 7. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET – BY
APPLICATION
7.1. Introduction
7.2. Trisomy
7.3. Microdeletion Syndrome
7.4. Other Applications
CHAPTER 8. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET – BY END
USER
8.1 Introduction
8.2 Diagnostic Laboratories
8.3 Hospitals
CHAPTER 9. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET - BY
GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.2.4. Costa Rica
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Chile
9.3.4. Columbia
9.3.5. Others
9.4. Europe
9.4.1. U.K.
9.4.2. Germany
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Russia
9.4.7. Netherlands
9.4.8. Switzerland
9.4.9. Poland
9.4.10. Others
9.5. A9PAC
9.5.1. China
9.5.2. Japan
9.5.3. India
9.5.4. South Korea
9.5.5. Australia & New Zealand
9.5.6. Malaysia
9.5.7. Singapore
9.5.8. Others
9.6. Middle East & Africa
9.6.1. UAE
9.6.2. Saudi Arabia
9.6.3. Iran
9.6.4. Iraq
9.6.5. Qatar
9.6.6. South Africa
9.6.7. Algeria
9.6.8. Morocco
9.6.9. Nigeria
9.6.10. Egypt
9.6.11. Others
CHAPTER 10. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET -
COMPANY PROFILES
10.1. Introduction
10.2. Ge Healthcare
10.3. Koninklijke Philips N.V.
10.4. Illumina, Inc.
10.5. Thermo Fisher Scientific, Inc.
10.6. F. Hoffman-La Roche Ltd.
10.7. Pacific Biosciences of California, Inc.
10.8. Perkinelmer, Inc.
10.9. Qiagen N.V.
10.10. Agilent Technologies, Inc.
10.11. Beijing Genomics Institute
10.12. Ariosa Diagnostics, Inc.
10.13. Berry Genomics Co., Ltd.
10.14. BGI Diagnostics
10.15. Laboratory Corporation of America Holdings
CHAPTER 11. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET -
COMPETITIVE LANDSCAPE
11.1. Market Share Analysis
11.2. Strategies adopted by top companies
11.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 12. MARKET INSIGHTS
12.1. Industry Experts Insights
12.2. Analysts Opinions
12.3. Investment Opportunities
CHAPTER 13. APPENDIX
13.1. List of Tables
13.2. List of Figures
